Atezolizumab is a PD-L1 targeting antibody; nevertheless, it is associated with reduced efficacy when FGR and DKK1 levels are high, according to TISIDB, a database that documents tumor-immune interactions (Fig. 8B) [28–30]. This evidence concerns the gene DKK1 and neoplasm.